Last reviewed · How we verify
Ketorolac + Ranibizumab
Ketorolac reduces ocular inflammation via COX inhibition while ranibizumab blocks VEGF-A to inhibit pathological neovascularization in the eye.
Ketorolac reduces ocular inflammation via COX inhibition while ranibizumab blocks VEGF-A to inhibit pathological neovascularization in the eye. Used for Age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | Ketorolac + Ranibizumab |
|---|---|
| Sponsor | Università degli Studi di Brescia |
| Drug class | NSAID + anti-VEGF monoclonal antibody fragment |
| Target | COX enzymes (ketorolac); VEGF-A (ranibizumab) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ketorolac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin-mediated inflammation. Ranibizumab is a monoclonal antibody fragment that binds and neutralizes vascular endothelial growth factor A (VEGF-A), preventing its interaction with VEGF receptors and thereby suppressing abnormal blood vessel growth. The combination targets both inflammatory and angiogenic pathways implicated in retinal diseases.
Approved indications
- Age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
Common side effects
- Conjunctival hemorrhage
- Eye pain or irritation
- Floaters
- Increased intraocular pressure
- Gastrointestinal effects (ketorolac systemic)
Key clinical trials
- Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival (NA)
- Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac + Ranibizumab CI brief — competitive landscape report
- Ketorolac + Ranibizumab updates RSS · CI watch RSS
- Università degli Studi di Brescia portfolio CI